These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20410429)

  • 1. 1H MR spectroscopy of invasive ductal carcinoma: correlations with FDG PET and histologic prognostic factors.
    Tozaki M; Hoshi K
    AJR Am J Roentgenol; 2010 May; 194(5):1384-90. PubMed ID: 20410429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of breast cancer using proton MR spectroscopy: total choline peak integral and signal-to-noise ratio as prognostic indicators.
    Shin HJ; Baek HM; Cha JH; Kim HH
    AJR Am J Roentgenol; 2012 May; 198(5):W488-97. PubMed ID: 22528931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
    Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy.
    Uematsu T; Kasami M; Yuen S
    Breast Cancer; 2009; 16(2):97-104. PubMed ID: 18663562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study.
    Bartella L; Morris EA; Dershaw DD; Liberman L; Thakur SB; Moskowitz C; Guido J; Huang W
    Radiology; 2006 Jun; 239(3):686-92. PubMed ID: 16603660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of early response to neoadjuvant chemotherapy in breast cancer with (1)H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography.
    Tozaki M; Sakamoto M; Oyama Y; O'uchi T; Kawano N; Suzuki T; Yamashiro N; Ozaki S; Sakamoto N; Higa K; Abe S; Ogawa T; Fukuma E
    J Magn Reson Imaging; 2008 Aug; 28(2):420-7. PubMed ID: 18666159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer.
    Kim BS; Sung SH
    Ann Nucl Med; 2012 Feb; 26(2):175-83. PubMed ID: 22139552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical significance of standardized uptake value in breast cancer measured using 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
    Kim YH; Lee JA; Baek JM; Sung GY; Lee DS; Won JM
    Nucl Med Commun; 2015 Aug; 36(8):790-4. PubMed ID: 25932535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.
    Imbriaco M; Caprio MG; Limite G; Pace L; De Falco T; Capuano E; Salvatore M
    AJR Am J Roentgenol; 2008 Nov; 191(5):1323-30. PubMed ID: 18941064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy--initial results.
    Yeung DK; Cheung HS; Tse GM
    Radiology; 2001 Jul; 220(1):40-6. PubMed ID: 11425970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging.
    Watanabe H; Kanematsu M; Kondo H; Kako N; Yamamoto N; Yamada T; Goshima S; Hoshi H; Bae KT
    J Magn Reson Imaging; 2010 May; 31(5):1151-6. PubMed ID: 20432351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status with total choline concentration and tumor volume in breast cancer patients: an MRI and in vivo proton MRS study.
    Sah RG; Sharma U; Parshad R; Seenu V; Mathur SR; Jagannathan NR
    Magn Reson Med; 2012 Oct; 68(4):1039-47. PubMed ID: 22213087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
    Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
    Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of perfusion parameters on dynamic contrast-enhanced MRI with prognostic factors and subtypes of breast cancers.
    Koo HR; Cho N; Song IC; Kim H; Chang JM; Yi A; Yun BL; Moon WK
    J Magn Reson Imaging; 2012 Jul; 36(1):145-51. PubMed ID: 22392859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
    Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of primary tumor SUV
    Yoo J; Yoon HJ; Kim BS
    Ann Nucl Med; 2017 Jan; 31(1):19-28. PubMed ID: 27645144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration.
    Mahon MM; Williams AD; Soutter WP; Cox IJ; McIndoe GA; Coutts GA; Dina R; deSouza NM
    NMR Biomed; 2004 Feb; 17(1):1-9. PubMed ID: 15011245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.